Boost your innovation on MedFIT 2024
Are you ready to present your groundbreaking projects and technologies to an audience of MedTech, Diagnostic and Digital Health experts, investors, and potential collaborators? Then, the MedFIT pitch competition is for you!
Scheduled for December 3rd and 4th, 2024, in Lille, MedFIT is Europe’s unique event for innovation partnerships and investment round, bringing together 650 innovators, investors and industry leaders from the MedTech, Diagnostic and Digital Health sectors.
If you pitch at MedFIT, you will :
Gain validation and credibility
At MedFIT you'll have the opportunity to present your project to a highly specialised audience of industry leaders, investors and potential collaborators
Get expert feedback
Gain valuable insights from MedTech experts to refine and improve your initiatives
Gain global exposure
MedFIT attracts participants from around the world, giving you the opportunity to gain international exposure for your project
Stay ahead of the curve
By pitching at MedFIT, you'll position yourself at the forefront of these developments, ensuring your project remains relevant and competitive in an ever-changing market
How does it work ?
- Apply in the pitch competition category that best suits your project :
Start-up Slams
If you are a young promising company seeking to raise a seed or Series A financing round
Collaborative and Licensing Opportunity Presentations
If you are a TTO, university, research institute or a company with an early-stage technology looking to initiate a collaboration project and/or a licensing deal
2. Be selected by a jury composed of high-level representatives and international experts, our steering committee, from public and private institutions, MedTech industries and investors
3. Pitch and win : The most innovative start-up or project in the sector will be recognised and awarded
RDS : 2023 Start-up Slams winner
The Start-up Slams were won by RDS (Rhythm Diagnostic Systems) and their project MultiSense®, a comprehensive remote monitoring system.
“Participating in MedFIT 2023 and receiving the Innovation Award at the event was a big breath of motivation for the entire RDS team. And also a great recognition of all the work accomplished to bring to life the next generation of patient monitoring solutions. Much progress has been made since then. We have officially secured CE-mark for our MultiSense® solution early 2024. The product has also already garnered much interest from clinicians and has been selected for use in various groundbreaking projects, including hospital-university research programs and innovative oncology initiatives. We’re also gearing up for our Series A funding round in 2024. This will not only support the commercialization of MultiSense® across Europe but also fuel our ongoing product development efforts, launch new clinical trials, and pave the way for F.D.A. approval and release in the United States in 2025.” Pierre-Olivier Beal, Director of Marketing and Communication at RDS
